Hemorrhoid management in women: the role of tribenoside + lidocaine

Article Page

Abstract

Hemorrhoids are commonly reported in women. However, despite the high prevalence of hemorrhoids in women and the major impact of this condition on quality of life, specific evidence and recommendations on the treatment of hemorrhoids in women are scant. This paper reviews various options in current therapy for hemorrhoids in women—namely, medical intervention (topical and systemic drug therapy)—and discusses the available clinical evidence for an appropriate use of over-the-counter topical formulations for the symptomatic treatment of hemorrhoids. Its focus is on a medical preparation containing tribenoside + lidocaine, available as a rectal cream (tribenoside 5%/lidocaine 2%) and a suppository (tribenoside 400 mg/lidocaine 40 mg) and marketed under the brand Procto-Glyvenol® (Recordati, SpA, Italy). Given its rapid comprehensive efficacy on all the different symptoms of hemorrhoids, the tribenoside + lidocaine combination can find a place in the treatment of this hemorrhoidal disease. Importantly, its efficacy and tolerability have been formally evaluated in several well-conducted studies, some of which were specifically conducted in women. In particular, tribenoside + lidocaine can be safely administered in postpartum women and in pregnant women after the first trimester of pregnancy. In pregnant women, the tribenoside/lidocaine combination significantly improved both subjective and objective symptoms of hemorrhoids. Fast onset of symptom relief was reported from 10 minutes after administration, lasting up to 10–12 hours. On these bases, tribenoside + lidocaine can represent a fast, effective, and safe option to treat hemorrhoids when conservative therapy is indicated, and it deserves consideration as a first-line treatment of this disease in clinical practice.

Keywords: hemorrhoids, lidocaine, tribenoside, women’s medicine.

Citation: Kestřánek J. Hemorrhoid management in women: the role of tribenoside + lidocaine. Drugs in Context 2019; 8: 212602. DOI: 10.7573/dic.212602

Contributions: The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and has given his approval for this version to be published.

Disclosure and potential conflicts of interest: The author declares that he has no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/08/dic.212602-COI.pdf

Acknowledgments: Editorial assistance was provided by Chiara Degirolamo, PhD, Luca Giacomelli, PhD, and Aashni Shah, of Polistudium (Milan, Italy).

Funding declaration: Medical writing assistance was supported by Recordati, Milan, Italy.

Copyright: Copyright © 2019 Kestřánek J. https://doi.org/10.7573/dic.212602. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Kestřánek J. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/hemorrhoid-management-in-women-the-role-of-tribenoside-+-lidocaine

Correspondence: Jan Kestřánek, Department of Obstetrics and Gynaecology, University Hospital, Charles University, Hradec Kralove, Czech Republic. jan.kestranek@fnhk.cz

Provenance: Submitted; externally peer reviewed.

Submitted: 3 June 2019; Peer review comments to author: 27 June 2019; Revised manuscript received: 29 July 2019; Accepted: 31 July 2019; Publication date: 13 September 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF